Diverse in our backgrounds, training, and thinking
United in our mission
We are a lively mix of biologists, data scientists, chemists, engineers, drug developers, and operators. We were founded with the mindset that great talent and science transcend borders and important unmet needs exist everywhere, and we are proudly situated in Singapore and the San Francisco Bay Area. Operating closely and collaboratively across sites, functions, and disciplines is in our DNA, and our diversity makes us stronger.
Our Team
Jeffrey Lu
Co-Founder & CEO
Jeffrey Lu
In addition to Engine, Jeff has played founding and leadership roles in several biotechnology and technology companies. This includes Enleofen Bio (developing therapeutics targeting IL-11 for fibrosis; preclinical pipeline acquired by Boehringer Ingelheim for >$1 billion), PairX Bio (venture-backed cancer immunotherapy company), and AAE (travel technology company built to >$100 million revenue and profitability within three years of inception; acquired by Expedia Inc in transactions valuing AAE at ~$300 million), among others.
Jeff began his career as a management consultant at Bain & Company. Subsequently he joined AirAsia as Head of Strategy and Group Head of Commercial Strategy, leading teams covering strategy, commercial strategy, data analytics, and digital marketing. He played a principal role in establishing several new joint ventures and businesses for the group.
Jeff has been named a Young Global Leader by the World Economic Forum. He received his BA summa cum laude from University of Pennsylvania.
Robert (Bob) Abraham PhD
Chief Scientific Officer
Robert (Bob) Abraham PhD
Robert (Bob) Abraham, PhD, serves as Chief Scientific Officer (CSO) of Engine Biosciences. Bob brings over three decades of experience leading scientific and translational efforts in oncology and has contributed to the development of 11 FDA-approved oncology drugs.
He most recently served as Executive Vice President and Head of Cancer Biology at Odyssey Therapeutics and previously as Chief Scientific Officer at Vividion Therapeutics (acquired by Bayer). In a decade at Pfizer, Bob served as Senior Vice President and Worldwide Head of the Oncology R&D group, where he led global cancer drug discovery and early clinical development to deliver impactful cancer medicines. He joined Pfizer following the acquisition of Wyeth, where he served as Head of Oncology Discovery Research.
Prior to joining the industry, Bob was a Professor at the Sanford-Burnham-Prebys Medical Discovery Institute and held an Endowed Chair in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center. Bob held dual Professorships in the Department of Immunology and the Department of Pharmacology at the Mayo Clinic in Rochester, MN, where he also served as Director of Basic Sciences in the Mayo Comprehensive Cancer Center.
Bob’s research interests include cancer biology, immunology, and signal transduction. He has authored over 230 scientific publications with over 59,000 citations and received numerous awards for his contributions.
Bob received his B.S. in Biology from Bucknell University and his Ph.D. in Pharmacology from the University of Pittsburgh and completed his postdoctoral training in Pharmacology and Immunology at the Mayo Clinic.
Yaron Turpaz PhD
Chief Information Officer
Yaron Turpaz PhD
Previously, he held senior R&D informatics roles at Human Longevity Inc (Chief Information Officer), AstraZeneca (VP R&D IT), Eli Lilly (Director), and Affymetrix in California, Boston, and Singapore. He has led global teams of up to 300 headcount and has worked across many therapeutic areas including oncology, neuroscience, infectious diseases, diabetes, and cardiovascular. He also has a role at Global Gene Corp as Chief Data and Technology Officer.
Yaron has a BS in Biology from Tel Aviv University, a Ph.D. in Bioengineering from the University of Illinois and an MBA from the University of Chicago, Booth School of Business. He also held an adjunct assistant professor at the Centre for Quantitative Medicine of Duke-National University of Singapore, Graduate Medical School.
David Epstein PhD
Interim R&D Head
David Epstein PhD
David M. Epstein, Ph.D., has served as Scientific Advisor to Engine Bio since 2017, and in 2023, assumed the additional role of Head of R&D. David is a biopharmaceutical leader and executive who has successfully led large and small R&D teams in academic, start-up, mid-size, and global large-pharmaceutical settings. David’s teams have progressed more than a dozen novel agents through clinical development in oncology, cardiovascular disease, and retinal degeneration; and this work has led to one approved medicine and the formation of four venture-backed healthcare companies; Archemix, Black Diamond Therapeutics, PairX Bio and Launchpad Therapeutics.
David is the former President & CEO of Black Diamond Therapeutics where he served from its scientific founding in 2016 until through clinical proof-of-concept in 2023. He cumulatively raised over $475 million in private and public financing, including IPO on NASDAQ in 2020.
Prior to his appointment as Black Diamond’s President and CEO, David was Vice Dean, Innovation & Entrepreneurship, at Duke-NUS Medical School, Singapore, establishing both the Office of Innovation & Entrepreneurship and its Center for Technology & Development. David was Associate Professor in the Cancer & Stem Cell Biology Program at Duke-NUS establishing a research program focused on the role of defective mRNA splicing in cancer. This work resulted in the simultaneous discovery of splicing-derived shared tumor antigens and their cognate TCRs, leading to PairX Bio, a Precision Immuno-Oncology company.
Previously, he was Chief Scientific Officer at OSI Pharmaceuticals, acquired by Astellas Pharma for over $4 billion in 2010. David was scientific founder and an executive at Archemix Corp, where he was inventor of avacincaptad pegol (Izervay™) an anti-C5 aptamer for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Izervay™ was acquired by Iveric Bio and sold to Astellas for $5.9 billion in 2023.
David earned a Ph.D. in Biochemistry at Brandeis University and completed a joint post-doctoral fellowship, leading a collaboration in protein structure, function, and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla, California. He received a B.Sc. in Chemistry from Lewis & Clark College.
Karsten Witt MD
Clinical Development
Karsten Witt MD
Karsten is leading Engine’s clinical development strategies. He brings more than 30 years of clinical development experience, including eight successful new drug applications, in the areas of oncology and inflammatory disease, having served in senior leadership positions for companies including Black Diamond Therapeutics, Array Biopharma, OSI Pharmaceuticals, Gilead, NeXstar, and Amgen.
Among his many achievements, Karsten was intimately involved in the clinical development of Tarceva® (erlotinib) for advanced non-small cell lung cancer, pancreatic cancer, hepatocellular cancer, and other solid tumors, as well as the parallel development of biomarkers and companion diagnostics.
He has served on Executive Management Committees, Global Development Committees, and as a member of the Board of Directors for Danish pharmaceutical company Topotarget until its merger with the French company BioAlliance resulting in the formation of Onxeo.
Karsten earned his M.D. from the University of Copenhagen and practiced medicine at Hvidovre University Hospital in Copenhagen in the internal medicine subspecialties of gastroenterology, infectious disease, and cardiology, before transitioning to industry.
Jeffrey Lu
Co-Founder & CEO
Jeffrey Lu
In addition to Engine, Jeff has played founding and leadership roles in several biotechnology and technology companies. This includes Enleofen Bio (developing therapeutics targeting IL-11 for fibrosis; preclinical pipeline acquired by Boehringer Ingelheim for >$1 billion), PairX Bio (venture-backed cancer immunotherapy company), and AAE (travel technology company built to >$100 million revenue and profitability within three years of inception; acquired by Expedia Inc in transactions valuing AAE at ~$300 million), among others.
Jeff began his career as a management consultant at Bain & Company. Subsequently he joined AirAsia as Head of Strategy and Group Head of Commercial Strategy, leading teams covering strategy, commercial strategy, data analytics, and digital marketing. He played a principal role in establishing several new joint ventures and businesses for the group.
Jeff has been named a Young Global Leader by the World Economic Forum. He received his BA summa cum laude from University of Pennsylvania.
Timothy Lu MD PhD
Co-Founder and Co-Chair of Scientific Advisory Board
Timothy Lu MD PhD
Tim is an Associate Professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Tim graduated with his SB and MEng from MIT, and his MD/PhD from the Harvard-MIT Health Sciences and Technology program. He is a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies innovating new diagnostic and therapeutic technologies for human health, including Sample6, Senti Biosciences, Synlogic, Eligo Biosciences, BiomX, and Engine Biosciences. He currently serves as CEO of Senti Biosciences.
Tim’s research at MIT focuses on engineering platforms for computing and memory in living cells and applying these to create adaptive medicines as next-generation cell and gene therapies for important human diseases. His work also includes developing novel technology platforms to interrogate and correct diseased cell states. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.
Amy Schulman JD
Managing Partner, Polaris Partners
Amy Schulman JD
She currently serves as executive chair of SQZ Biotech, as well as Lyndra Therapeutics, where she was co-founder and the company’s initial CEO. She also represents Polaris as a director of Kallyope, Volastra, Thirty Madison and ByHeart. Amy joined Polaris in 2014, at which time she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company later acquired by Eagle Pharmaceuticals. She also manages the Polaris Innovation Fund which was formed in 2017.
Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and was instrumental in its sale to Nestle for $11.85 billion in 2012. Soon after, Schulman became the president of Pfizer Consumer Healthcare.
Schulman has received numerous awards including 2019 PharmaVoice 100, Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Mount Sinai Hospital. She is also a member of Singapore’s Health and Biomedical Sciences International Advisory Council.
She is a Phi Beta Kappa graduate of Wesleyan University with a joint degree in philosophy and english and earned her J.D. from Yale Law School.
Wen Qi Ho PhD
Director – Investments, ClavystBio
Wen Qi Ho PhD
Wen Qi is an advocate for early career researcher participation in biotech entrepreneurship, and serves on advisory and grant review panels with leading institutions in Singapore. She also serves on boards of ClavystBio’s portfolio companies.
Wen Qi attained her PhD in Immunology at Stanford University, and BSc in Molecular and Cellular Biology at Johns Hopkins University.
Leon Chen PhD
Founding Partner and CEO, 6 Dimensions Capital
Leon Chen PhD
As a venture capital investor, his past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Board Director, Acting CFO), Cathay Industrial Biotechnology (Board Director), Hile Biopharma (Board Director), Hua Medicine (Shanghai) (Board Director), Innovent Biologics Ltd (Chairman), Adagene (Board Director) and MDDF (Board Director).
As a management consultant, his past affiliations include McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area). As a Ph.D. scientist, he worked with Schering Plough (New Jersey), and is a key member of the discovery team of Zytia / Vytorin – a multi-billion drug. Leon was a Post-Doc at MIT and received his Ph.D. (with top honors) from the University of Louvain, Louvain-La-Neuve and his B.S. from Peking University. Leon holds 6 issued US Patents, and is co-author of the 14th and 15th Ernst & Young Biotechnology Annual Report.
Ali Farahanchi PhD
Managing Director, Camford Capital
Ali Farahanchi PhD
Board Observers
Nirdesh Gupta PhD
Managing Director, Cedars-Sinai Technology Ventures
Nirdesh Gupta PhD
Dr. Gupta works closely with, and mentors, world-class scientists and entrepreneurs to build companies to develop innovative products and platforms that address critical healthcare needs. Dr. Gupta and his team support company creation, equity and IP portfolio management, preclinical and clinical development of breakthrough technologies, business development, licensing & industry alliances including pilot programs and co-development partnerships with startups and major industry players. Dr. Gupta’s leadership has led to multiple successful partnerships with industry, and he has directly played an instrumental role in company co-creation of several Cedars-Sinai spinoffs notably Prometheus Biosciences, Gemelli Biotech, and Gravidas Diagnostics.
Dr. Gupta was a nominated member of the Business Advisory Council of the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP) and has served as member of their Innovation and Competitiveness Task Force. He holds a bachelor’s and doctorate degrees in pharmaceutical sciences.
Alexandra Cantley PhD
Partner, Polaris Partners
Alexandra Cantley PhD
She currently serves on the Board of Directors of Auron Therapeutics, BeMeHealth, Crossbow Therapeutics, EpiBiologics, Podimetrics, SunBird Bio, and TRex Bio, and as a Board Observer to Capstan Therapeutics and Engine Bio.
Prior to joining Polaris, Alexandra was part of the initial research team at Inzen Therapeutics, where she helped develop their platform technologies. She moved to Inzen from Vertex Pharmaceuticals, where she held a research fellowship.
Alexandra received a PhD in Chemical Biology from Harvard University, where she studied natural product discovery. Alexandra performed her undergraduate studies at New York University.
Joy Ho PhD
Senior Lead – Investments, EDBI
Joy Ho PhD
Before beginning her investing career, Joy was a lung cancer program manager at Genome Institute of Singapore and prior to that, she was a researcher at Prof Sydney Brenner’s Molecular Engineering Lab. She also did a stint in biopharma manufacturing at Genentech in North America.
She graduated with a DPhil in Clinical Medicine, and Saïd Business School’s Finance Lab from University of Oxford. She received her Bachelor’s degree in Material Science and Engineering from Nanyang Technological University.
Scientific Founder
Timothy Lu MD PhD
Co-Founder and Co-Chair of Scientific Advisory Board
Timothy Lu MD PhD
Tim is an Associate Professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Tim graduated with his SB and MEng from MIT, and his MD/PhD from the Harvard-MIT Health Sciences and Technology program. He is a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies innovating new diagnostic and therapeutic technologies for human health, including Sample6, Senti Biosciences, Synlogic, Eligo Biosciences, BiomX, and Engine Biosciences. He currently serves as CEO of Senti Biosciences.
Tim’s research at MIT focuses on engineering platforms for computing and memory in living cells and applying these to create adaptive medicines as next-generation cell and gene therapies for important human diseases. His work also includes developing novel technology platforms to interrogate and correct diseased cell states. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.
Scientific Founder
James Collins PhD
Founding Co-Chair of Scientific Advisory Board
James Collins PhD
In addition to his role as a faculty member at MIT, Jim is a Core Faculty member of the Wyss Institute at Harvard and an Institute Member of the Broad Institute of MIT and Harvard. Jim is a member of all three National Academies, and has been a Rhodes Scholar, a Macarthur Fellow, and a recipient of the NIH Pioneer Award. He is a co-founder of Senti, EnBiotix, Synlogic (NASDAQ: SYBX) and Sherlock Biosciences. Dr. Collins’ patented technologies have been licensed by over 25 biotech, pharma, and medical device companies.
Drug Discovery
Nicholas Saccomano PhD
Scientific Advisor
Nicholas Saccomano, PhD
Drug Discovery
George Trainor PhD
Scientific Advisor
George Trainor PhD
Dr. Trainor brings 30 years of experience in the Biotechnology and Pharmaceutical Industries. He has expertise in overall drug discovery strategy and execution, medicinal chemistry, and the application of transformative technologies. Leading teams of over 100 scientists, he has advanced over 35 drug candidates into clinical development in a diverse spectrum of therapeutic areas including antivirals, cancer, neuroscience, and inflammation. His team provided key discovery support that enabled the successful launch of SustivaTM for HIV disease.
Dr. Trainor is a partner at BioMotiv which he joined after leaving Bristol Myers Squibb Company as Vice President of Oncology and Early Discovery Chemistry. At BMS George was responsible for all aspects of medicinal chemistry for the oncology area as well as hit-to-leads activities in support of all therapeutic areas. Prior to being merged into Bristol Myers Squibb, Dr. Trainor was Executive Director for Medicinal Chemistry at Dupont/Dupont Merck Pharmaceuticals. His key contribution from that period was the discovery and commercial development of fluorescence-tagged chain terminators for use in automated DNA sequencing. This breakthrough technology was subsequently employed in the sequencing of the human genome, and In 2011, Trainor won the American Chemical Society’s Heroes of Chemistry Award for his work on DNA sequencing. Dr. Trainor did his undergraduate work at Stevens Institute of Technology, received his PhD in Organic Chemistry at Harvard University, and was an NIH Postdoctoral Fellow at Columbia University.
Clinical
José Iglesias, M.D.
Scientific Advisor (Clinical)
José Iglesias, M.D.
José Iglesias, M.D., is consultant chief medical officer at HiberCell. He has more than 30 years of experience in oncology. Prior to working with HiberCell, José was vice president and head of translational medicine at Boston Biomedical Inc., where he was responsible for the clinical development of seven early pipeline compounds in immuno-oncology, solid tumor oncology and hematologic malignancies.
Previously, José was chief medical officer at Biothera where he was responsible for the clinical development program of Imprime-PGG. Prior to that, he was the chief medical officer for Bionomics where he was responsible for the clinical development of its oncology pipeline, including antivascular agents, monoclonal antibodies and small molecule kinase inhibitors. Before that, he served as vice president, clinical development, at Celgene Corporation, where he was responsible for the Phase III development of Abraxane in pancreatic cancer, lung cancer and metastatic breast cancer.
José is author or co-author of more than 60 publications in the area of Oncology, with over 6,000 citations. He received his M.D. in oncology and cancer biology from the Universidad de Montevideo, Uruguay.
Drug Discovery
Martin Kampmann PhD
Scientific Advisor
Martin Kampmann PhD
Martin is a member of Engine Biosciences’s Scientific Advisory Board, with deep experience in functional genomics technology development and applications in cancer and neurodegenerative disease. He is an Associate Professor in the UCSF Department of Biochemistry and Biophysics and the Institute for Neurodegenerative Diseases at UCSF. He received his BA and MA in Natural Sciences (Biochemistry) from Cambridge University and his PhD from the Rockefeller University, where he used biophysical approaches to characterize the architecture and dynamics of the nuclear pore complex with Dr. Günter Blobel.
As a postdoctoral fellow in Dr. Jonathan Weissman’s group at UCSF, Martin spearheaded the development of a functional genomics platform that makes it possible to robustly identify human genes relevant to a cellular process of interest, and to elucidate cellular pathways and networks using systematic genetic interaction maps. One important application of the screening platform is the identification of genes that control the sensitivity of cells to a given drug. This approach can identify the relevant cellular targets of new compounds, predict drug-resistance mechanisms, and guide the rational development of combination therapies.
Currently, the goal of Martin’s research is to understand how human cells maintain their proteins in a functional and balanced state. The cellular pathways safeguarding proteome function and balance are termed the “proteostasis network.” Martin aims to elucidate how the proteostasis network dynamically adapts to the needs of the cell and how it is challenged and rewired in diseases, especially cancer and neurodegenerative diseases. Identification of proteostasis factors that control formation, spread, and clearance of protein aggregates associated with neurodegenerative diseases will shed light on the disease mechanisms and reveal potential therapeutic targets.
Martin has received several highly prestigious awards, including the NIH Director’s New Innovator Award (2015), the Paul G. Allen Family Foundation’s Allen Distinguished Investigator Award (2015), and the NIH Pathway to Independence Award (2014). The Kampmann lab is affiliated with the Innovative Genomics Initiative and the Paul F. Glenn Center for Aging Research at UC Berkeley and UCSF.
Scientific Founder
Prashant Mali PhD
Scientific Founder and Advisor
Prashant Mali PhD
Prashant is an Associate Professor in the Department of Bioengineering at the University of California San Diego. His research is in the fields of synthetic biology and regenerative medicine, with a long-term focus on developing tools for enabling gene and cell based human therapeutics. In this regard, he has helped pioneer the development of CRISPR-Cas9, a powerful genome editing tool derived from microbial systems, with wide applications in both basic biology and human therapeutics. More recently, he is focused on the development of RNA and protein targeting tools derived from endogenous human systems.
Prashant received his Bachelor’s and Master’s degrees in Electrical Engineering from the Indian Institute of Technology Bombay, a doctorate in Biomedical Engineering at the Johns Hopkins University, and a postdoctoral fellowship in the Department of Genetics at the Harvard Medical School. He has received multiple awards including the Siebel Scholar Award, the Burroughs Wellcome Career Award, the March of Dimes Basil O’Conner Scholar Award, the Kimmel Scholar Award, Kavli Frontiers of Science Fellow, and the Young Alumnus Achiever Award from the Indian Institute of Technology Bombay.
Scientific Founder
Hu Li PhD
Scientific Founder and Advisor
Hu Li PhD
Hu is an Associate Professor at the Mayo Clinic. His group is focused on systems pharmacology and individualized systems medicine. Li’s team is active in developing novel network tools and harnessing machine learning methods to study context-dependent activities of regulatory networks at genome-wide scale. The major theme in the research team is to develop novel computational methods that can detect meaningful biological information embedded in the sea of Big Data and uncover novel regulatory mechanisms that explain the properties of biological phenotypes to benefit individualized disease diagnosis, drug discovery, and precision medicine. The developed computational platforms can greatly illuminate the understanding of disease mechanisms underlying drugs’ modes of action, addressing key challenges in Big Data-oriented biomedical complex systems and will ultimately lead to precision medicine for each patient suffering from a devastating disease.
Hu completed his post-doctoral fellowship in systems biology at the Wyss Institute at Harvard Medical School and received his Ph.D. in computational biology and bioinformatics from the National University of Singapore.
- Management
-
Jeffrey Lu
Co-Founder & CEO
View BioJeffrey Lu
Jeff is passionate about building companies using technology and science for impact. He has fifteen years of business, executive management, and entrepreneurial experience, creating sustainable businesses, shareholder value and liquidity events.
In addition to Engine, Jeff has played founding and leadership roles in several biotechnology and technology companies. This includes Enleofen Bio (developing therapeutics targeting IL-11 for fibrosis; preclinical pipeline acquired by Boehringer Ingelheim for >$1 billion), PairX Bio (venture-backed cancer immunotherapy company), and AAE (travel technology company built to >$100 million revenue and profitability within three years of inception; acquired by Expedia Inc in transactions valuing AAE at ~$300 million), among others.
Jeff began his career as a management consultant at Bain & Company. Subsequently he joined AirAsia as Head of Strategy and Group Head of Commercial Strategy, leading teams covering strategy, commercial strategy, data analytics, and digital marketing. He played a principal role in establishing several new joint ventures and businesses for the group.Jeff has been named a Young Global Leader by the World Economic Forum. He received his BA summa cum laude from University of Pennsylvania.
CloseRobert (Bob) Abraham PhD
Chief Scientific Officer
View BioRobert (Bob) Abraham PhD
Robert (Bob) Abraham, PhD, serves as Chief Scientific Officer (CSO) of Engine Biosciences. Bob brings over three decades of experience leading scientific and translational efforts in oncology and has contributed to the development of 11 FDA-approved oncology drugs.
He most recently served as Executive Vice President and Head of Cancer Biology at Odyssey Therapeutics and previously as Chief Scientific Officer at Vividion Therapeutics (acquired by Bayer). In a decade at Pfizer, Bob served as Senior Vice President and Worldwide Head of the Oncology R&D group, where he led global cancer drug discovery and early clinical development to deliver impactful cancer medicines. He joined Pfizer following the acquisition of Wyeth, where he served as Head of Oncology Discovery Research.
Prior to joining the industry, Bob was a Professor at the Sanford-Burnham-Prebys Medical Discovery Institute and held an Endowed Chair in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center. Bob held dual Professorships in the Department of Immunology and the Department of Pharmacology at the Mayo Clinic in Rochester, MN, where he also served as Director of Basic Sciences in the Mayo Comprehensive Cancer Center.
Bob’s research interests include cancer biology, immunology, and signal transduction. He has authored over 230 scientific publications with over 59,000 citations and received numerous awards for his contributions.
Bob received his B.S. in Biology from Bucknell University and his Ph.D. in Pharmacology from the University of Pittsburgh and completed his postdoctoral training in Pharmacology and Immunology at the Mayo Clinic.
CloseYaron Turpaz PhD
Chief Information Officer
View BioYaron Turpaz PhD
Yaron joined Engine in 2018 and is a proven research and development informatics, data science and technology leader in the biotech and pharma space with hands-on experience using cloud-based high-throughput computational, machine learning, AI and genomics platforms for drug discovery and development applications in precision medicine.
Previously, he held senior R&D informatics roles at Human Longevity Inc (Chief Information Officer), AstraZeneca (VP R&D IT), Eli Lilly (Director), and Affymetrix in California, Boston, and Singapore. He has led global teams of up to 300 headcount and has worked across many therapeutic areas including oncology, neuroscience, infectious diseases, diabetes, and cardiovascular. He also has a role at Global Gene Corp as Chief Data and Technology Officer.Yaron has a BS in Biology from Tel Aviv University, a Ph.D. in Bioengineering from the University of Illinois and an MBA from the University of Chicago, Booth School of Business. He also held an adjunct assistant professor at the Centre for Quantitative Medicine of Duke-National University of Singapore, Graduate Medical School.
CloseCloseDavid Epstein PhD
Interim R&D Head
View BioDavid Epstein PhD
David M. Epstein, Ph.D., has served as Scientific Advisor to Engine Bio since 2017, and in 2023, assumed the additional role of Head of R&D. David is a biopharmaceutical leader and executive who has successfully led large and small R&D teams in academic, start-up, mid-size, and global large-pharmaceutical settings. David’s teams have progressed more than a dozen novel agents through clinical development in oncology, cardiovascular disease, and retinal degeneration; and this work has led to one approved medicine and the formation of four venture-backed healthcare companies; Archemix, Black Diamond Therapeutics, PairX Bio and Launchpad Therapeutics.
David is the former President & CEO of Black Diamond Therapeutics where he served from its scientific founding in 2016 until through clinical proof-of-concept in 2023. He cumulatively raised over $475 million in private and public financing, including IPO on NASDAQ in 2020.
Prior to his appointment as Black Diamond’s President and CEO, David was Vice Dean, Innovation & Entrepreneurship, at Duke-NUS Medical School, Singapore, establishing both the Office of Innovation & Entrepreneurship and its Center for Technology & Development. David was Associate Professor in the Cancer & Stem Cell Biology Program at Duke-NUS establishing a research program focused on the role of defective mRNA splicing in cancer. This work resulted in the simultaneous discovery of splicing-derived shared tumor antigens and their cognate TCRs, leading to PairX Bio, a Precision Immuno-Oncology company.
Previously, he was Chief Scientific Officer at OSI Pharmaceuticals, acquired by Astellas Pharma for over $4 billion in 2010. David was scientific founder and an executive at Archemix Corp, where he was inventor of avacincaptad pegol (Izervay™) an anti-C5 aptamer for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Izervay™ was acquired by Iveric Bio and sold to Astellas for $5.9 billion in 2023.
David earned a Ph.D. in Biochemistry at Brandeis University and completed a joint post-doctoral fellowship, leading a collaboration in protein structure, function, and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla, California. He received a B.Sc. in Chemistry from Lewis & Clark College.
CloseKarsten Witt MD
Clinical Development
View BioKarsten Witt MD
Karsten is leading Engine’s clinical development strategies. He brings more than 30 years of clinical development experience, including eight successful new drug applications, in the areas of oncology and inflammatory disease, having served in senior leadership positions for companies including Black Diamond Therapeutics, Array Biopharma, OSI Pharmaceuticals, Gilead, NeXstar, and Amgen.
Among his many achievements, Karsten was intimately involved in the clinical development of Tarceva® (erlotinib) for advanced non-small cell lung cancer, pancreatic cancer, hepatocellular cancer, and other solid tumors, as well as the parallel development of biomarkers and companion diagnostics.
He has served on Executive Management Committees, Global Development Committees, and as a member of the Board of Directors for Danish pharmaceutical company Topotarget until its merger with the French company BioAlliance resulting in the formation of Onxeo.
Karsten earned his M.D. from the University of Copenhagen and practiced medicine at Hvidovre University Hospital in Copenhagen in the internal medicine subspecialties of gastroenterology, infectious disease, and cardiology, before transitioning to industry.
Close - Board Of Directors
-
Jeffrey Lu
Co-Founder & CEO
View BioJeffrey Lu
Jeff is passionate about building companies using technology and science for impact. He has fifteen years of business, executive management, and entrepreneurial experience, creating sustainable businesses, shareholder value and liquidity events.
In addition to Engine, Jeff has played founding and leadership roles in several biotechnology and technology companies. This includes Enleofen Bio (developing therapeutics targeting IL-11 for fibrosis; preclinical pipeline acquired by Boehringer Ingelheim for >$1 billion), PairX Bio (venture-backed cancer immunotherapy company), and AAE (travel technology company built to >$100 million revenue and profitability within three years of inception; acquired by Expedia Inc in transactions valuing AAE at ~$300 million), among others.
Jeff began his career as a management consultant at Bain & Company. Subsequently he joined AirAsia as Head of Strategy and Group Head of Commercial Strategy, leading teams covering strategy, commercial strategy, data analytics, and digital marketing. He played a principal role in establishing several new joint ventures and businesses for the group.Jeff has been named a Young Global Leader by the World Economic Forum. He received his BA summa cum laude from University of Pennsylvania.
CloseTimothy Lu MD PhD
Co-Founder and Co-Chair of Scientific Advisory Board
View BioTimothy Lu MD PhD
Tim developed key elements of Engine Bio’s technology platforms and has deep expertise in synthetic and systems biology, genetic interactions mapping, and computer science/engineering.Tim is an Associate Professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Tim graduated with his SB and MEng from MIT, and his MD/PhD from the Harvard-MIT Health Sciences and Technology program. He is a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies innovating new diagnostic and therapeutic technologies for human health, including Sample6, Senti Biosciences, Synlogic, Eligo Biosciences, BiomX, and Engine Biosciences. He currently serves as CEO of Senti Biosciences.
Tim’s research at MIT focuses on engineering platforms for computing and memory in living cells and applying these to create adaptive medicines as next-generation cell and gene therapies for important human diseases. His work also includes developing novel technology platforms to interrogate and correct diseased cell states. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.
CloseAmy Schulman JD
Managing Partner, Polaris Partners
View BioAmy Schulman JD
Amy is a managing partner of Polaris Partners in the New York office and focuses on investments in healthcare companies.She currently serves as executive chair of SQZ Biotech, as well as Lyndra Therapeutics, where she was co-founder and the company’s initial CEO. She also represents Polaris as a director of Kallyope, Volastra, Thirty Madison and ByHeart. Amy joined Polaris in 2014, at which time she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company later acquired by Eagle Pharmaceuticals. She also manages the Polaris Innovation Fund which was formed in 2017.
Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and was instrumental in its sale to Nestle for $11.85 billion in 2012. Soon after, Schulman became the president of Pfizer Consumer Healthcare.Schulman has received numerous awards including 2019 PharmaVoice 100, Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Mount Sinai Hospital. She is also a member of Singapore’s Health and Biomedical Sciences International Advisory Council.
She is a Phi Beta Kappa graduate of Wesleyan University with a joint degree in philosophy and english and earned her J.D. from Yale Law School.
CloseWen Qi Ho PhD
Director – Investments, ClavystBio
View BioWen Qi Ho PhD
Wen Qi focuses on investing in and building global healthcare companies from Singapore. Prior to joining ClavystBio, she headed up the Singapore investments and operations for Lightstone Ventures, where she played a major role in establishing the firm’s presence in Singapore. Wen Qi evaluated new investment opportunities in the biopharmaceutical and medical device sectors, and was actively involved in venture-building portfolio companies in Singapore such as Medisix Therapeutics, Allay Therapeutics and Ligature Therapeutics.Wen Qi is an advocate for early career researcher participation in biotech entrepreneurship, and serves on advisory and grant review panels with leading institutions in Singapore. She also serves on boards of ClavystBio’s portfolio companies.
Wen Qi attained her PhD in Immunology at Stanford University, and BSc in Molecular and Cellular Biology at Johns Hopkins University.
CloseLeon Chen PhD
Founding Partner and CEO, 6 Dimensions Capital
View BioLeon Chen PhD
Leon is Founding Partner and CEO of 6 Dimensions Capital, a leading biotech venture capital firm with over $1.5 billion in AUM. Leon has over 20 years of experience in the life sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor. He is a member of the Expert Review Panel for the Chinese Central Government HR’s 1000 Talent Project, and an adviser to BioBAY of Suzhou Industry Park.As a venture capital investor, his past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Board Director, Acting CFO), Cathay Industrial Biotechnology (Board Director), Hile Biopharma (Board Director), Hua Medicine (Shanghai) (Board Director), Innovent Biologics Ltd (Chairman), Adagene (Board Director) and MDDF (Board Director).
As a management consultant, his past affiliations include McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area). As a Ph.D. scientist, he worked with Schering Plough (New Jersey), and is a key member of the discovery team of Zytia / Vytorin – a multi-billion drug. Leon was a Post-Doc at MIT and received his Ph.D. (with top honors) from the University of Louvain, Louvain-La-Neuve and his B.S. from Peking University. Leon holds 6 issued US Patents, and is co-author of the 14th and 15th Ernst & Young Biotechnology Annual Report.
CloseAli Farahanchi PhD
Managing Director, Camford Capital
View BioAli Farahanchi PhD
Ali is Managing Director at Camford Capital, an early-stage tech and life science fund in Silicon Valley. With more than $650M assets under management and 100+ companies in its portfolio, Camford invests in variety of areas in healthcare including therapeutics, diagnostics and tools, and digital health, with strong emphasis on novel mechanisms and data-driven platforms. Previously Ali worked in research and in consulting roles in semiconductor and healthcare industries. He obtained graduate degrees in engineering and management from MIT and University of Chicago.CloseBoard Observers
Nirdesh Gupta PhD
Managing Director, Cedars-Sinai Technology Ventures
View BioNirdesh Gupta PhD
Nirdesh K. Gupta, PhD, is Managing Director of Cedars-Sinai Technology Ventures and the Cedars-Sinai Accelerator. Dr. Gupta also leads and provides key operations leadership to Business Units and Commercial Enterprises at Cedars-Sinai such as 3rd Street Technologies, The Medically Associated Science and Technology (MAST) & Cedars-Sinai Biomanufacturing Center (CBC). Dr. Gupta directed CSTV’s Seed Fund and Equity investments and have $275M+ equity under management representing over 20 companies, with multiple significant financial exits.Dr. Gupta works closely with, and mentors, world-class scientists and entrepreneurs to build companies to develop innovative products and platforms that address critical healthcare needs. Dr. Gupta and his team support company creation, equity and IP portfolio management, preclinical and clinical development of breakthrough technologies, business development, licensing & industry alliances including pilot programs and co-development partnerships with startups and major industry players. Dr. Gupta’s leadership has led to multiple successful partnerships with industry, and he has directly played an instrumental role in company co-creation of several Cedars-Sinai spinoffs notably Prometheus Biosciences, Gemelli Biotech, and Gravidas Diagnostics.
Dr. Gupta was a nominated member of the Business Advisory Council of the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP) and has served as member of their Innovation and Competitiveness Task Force. He holds a bachelor’s and doctorate degrees in pharmaceutical sciences.
CloseAlexandra Cantley PhD
Partner, Polaris Partners
View BioAlexandra Cantley PhD
Alexandra joined Polaris in 2019 and serves as a partner in the New York office. She is primarily focused on early stage biotech and healthcare investments.She currently serves on the Board of Directors of Auron Therapeutics, BeMeHealth, Crossbow Therapeutics, EpiBiologics, Podimetrics, SunBird Bio, and TRex Bio, and as a Board Observer to Capstan Therapeutics and Engine Bio.
Prior to joining Polaris, Alexandra was part of the initial research team at Inzen Therapeutics, where she helped develop their platform technologies. She moved to Inzen from Vertex Pharmaceuticals, where she held a research fellowship.
Alexandra received a PhD in Chemical Biology from Harvard University, where she studied natural product discovery. Alexandra performed her undergraduate studies at New York University.
CloseJoy Ho PhD
Senior Lead – Investments, EDBI
View BioJoy Ho PhD
Currently looking at healthcare investments at EDBI, Joy identifies global investment opportunities across Biotech, Digital Health, and Medtech sectors. Her portfolio includes Aetion, Biofourmis, Engine Biosciences, Doctor Anywhere, Neuroglee, Genesis Medtech, us2.ai, and Foresite, etc. Prior to the current role, Joy was a venture capitalist at a fund that focuses on investing into early-stage startups, closing deals across deep technology verticals.Before beginning her investing career, Joy was a lung cancer program manager at Genome Institute of Singapore and prior to that, she was a researcher at Prof Sydney Brenner’s Molecular Engineering Lab. She also did a stint in biopharma manufacturing at Genentech in North America.
She graduated with a DPhil in Clinical Medicine, and Saïd Business School’s Finance Lab from University of Oxford. She received her Bachelor’s degree in Material Science and Engineering from Nanyang Technological University.
Close - Scientific Founders and Advisors
-
Scientific Founder
Timothy Lu MD PhD
Co-Founder and Co-Chair of Scientific Advisory Board
View BioTimothy Lu MD PhD
Tim developed key elements of Engine Bio’s technology platforms and has deep expertise in synthetic and systems biology, genetic interactions mapping, and computer science/engineering.Tim is an Associate Professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Tim graduated with his SB and MEng from MIT, and his MD/PhD from the Harvard-MIT Health Sciences and Technology program. He is a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies innovating new diagnostic and therapeutic technologies for human health, including Sample6, Senti Biosciences, Synlogic, Eligo Biosciences, BiomX, and Engine Biosciences. He currently serves as CEO of Senti Biosciences.
Tim’s research at MIT focuses on engineering platforms for computing and memory in living cells and applying these to create adaptive medicines as next-generation cell and gene therapies for important human diseases. His work also includes developing novel technology platforms to interrogate and correct diseased cell states. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.
CloseScientific Founder
James Collins PhD
Founding Co-Chair of Scientific Advisory Board
View BioJames Collins PhD
Jim is the Termeer Professor of Medical Engineering and Science in the Institute for Medical Engineering and Science as well as Professor of Biological Engineering at MIT. Jim is widely heralded as one of the founders of the field of synthetic biology, which applies engineering principles to the biological sciences in order to program novel gene circuits that can better control cellular behavior. Using this approach, Jim has pioneered innovative ways to detect and treat infections, and to study antibiotic action, bacterial defense mechanisms, and the emergence of resistance.In addition to his role as a faculty member at MIT, Jim is a Core Faculty member of the Wyss Institute at Harvard and an Institute Member of the Broad Institute of MIT and Harvard. Jim is a member of all three National Academies, and has been a Rhodes Scholar, a Macarthur Fellow, and a recipient of the NIH Pioneer Award. He is a co-founder of Senti, EnBiotix, Synlogic (NASDAQ: SYBX) and Sherlock Biosciences. Dr. Collins’ patented technologies have been licensed by over 25 biotech, pharma, and medical device companies.
CloseDrug Discovery
Nicholas Saccomano PhD
Scientific Advisor
View BioNicholas Saccomano, PhD
Nicholas A. Saccomano is a biopharmaceutical professional with nearly 35 years of extensive research, development and management experience across multiple therapeutic areas. He most recently worked at Pfizer R&D, Inc. as Chief Science Officer and Site Head at its Boulder facility, where he led a 170-person research and development team that advanced a portfolio of small molecule drug programs from inception to proof-of-concept. Prior to working at Pfizer, Dr. Saccomano served as Chief Science Officer at Array Biopharma Inc., where he was responsible for creating and advancing ten clinical-stage compounds, with seven drug approvals to date. Dr. Saccomano also served as Chief Technology Officer at SomaLogic Inc., where he managed scientific and technical teams in charge of advancing elements of the company’s proteomic platform. He currently serves as a scientific advisor to several innovative companies. Dr. Saccomano received a B.S. from the State University of New York at Buffalo and a Ph.D. in Organic Chemistry from Columbia University under the direction of Gilbert Stork.CloseDrug Discovery
George Trainor PhD
Scientific Advisor
View BioGeorge Trainor PhD
Dr. Trainor brings 30 years of experience in the Biotechnology and Pharmaceutical Industries. He has expertise in overall drug discovery strategy and execution, medicinal chemistry, and the application of transformative technologies. Leading teams of over 100 scientists, he has advanced over 35 drug candidates into clinical development in a diverse spectrum of therapeutic areas including antivirals, cancer, neuroscience, and inflammation. His team provided key discovery support that enabled the successful launch of SustivaTM for HIV disease.
Dr. Trainor is a partner at BioMotiv which he joined after leaving Bristol Myers Squibb Company as Vice President of Oncology and Early Discovery Chemistry. At BMS George was responsible for all aspects of medicinal chemistry for the oncology area as well as hit-to-leads activities in support of all therapeutic areas. Prior to being merged into Bristol Myers Squibb, Dr. Trainor was Executive Director for Medicinal Chemistry at Dupont/Dupont Merck Pharmaceuticals. His key contribution from that period was the discovery and commercial development of fluorescence-tagged chain terminators for use in automated DNA sequencing. This breakthrough technology was subsequently employed in the sequencing of the human genome, and In 2011, Trainor won the American Chemical Society’s Heroes of Chemistry Award for his work on DNA sequencing. Dr. Trainor did his undergraduate work at Stevens Institute of Technology, received his PhD in Organic Chemistry at Harvard University, and was an NIH Postdoctoral Fellow at Columbia University.
CloseClinical
José Iglesias, M.D.
Scientific Advisor (Clinical)
View BioJosé Iglesias, M.D.
José Iglesias, M.D., is consultant chief medical officer at HiberCell. He has more than 30 years of experience in oncology. Prior to working with HiberCell, José was vice president and head of translational medicine at Boston Biomedical Inc., where he was responsible for the clinical development of seven early pipeline compounds in immuno-oncology, solid tumor oncology and hematologic malignancies.
Previously, José was chief medical officer at Biothera where he was responsible for the clinical development program of Imprime-PGG. Prior to that, he was the chief medical officer for Bionomics where he was responsible for the clinical development of its oncology pipeline, including antivascular agents, monoclonal antibodies and small molecule kinase inhibitors. Before that, he served as vice president, clinical development, at Celgene Corporation, where he was responsible for the Phase III development of Abraxane in pancreatic cancer, lung cancer and metastatic breast cancer.
José is author or co-author of more than 60 publications in the area of Oncology, with over 6,000 citations. He received his M.D. in oncology and cancer biology from the Universidad de Montevideo, Uruguay.
CloseDrug Discovery
Martin Kampmann PhD
Scientific Advisor
View BioMartin Kampmann PhD
Martin is a member of Engine Biosciences’s Scientific Advisory Board, with deep experience in functional genomics technology development and applications in cancer and neurodegenerative disease. He is an Associate Professor in the UCSF Department of Biochemistry and Biophysics and the Institute for Neurodegenerative Diseases at UCSF. He received his BA and MA in Natural Sciences (Biochemistry) from Cambridge University and his PhD from the Rockefeller University, where he used biophysical approaches to characterize the architecture and dynamics of the nuclear pore complex with Dr. Günter Blobel.
As a postdoctoral fellow in Dr. Jonathan Weissman’s group at UCSF, Martin spearheaded the development of a functional genomics platform that makes it possible to robustly identify human genes relevant to a cellular process of interest, and to elucidate cellular pathways and networks using systematic genetic interaction maps. One important application of the screening platform is the identification of genes that control the sensitivity of cells to a given drug. This approach can identify the relevant cellular targets of new compounds, predict drug-resistance mechanisms, and guide the rational development of combination therapies.
Currently, the goal of Martin’s research is to understand how human cells maintain their proteins in a functional and balanced state. The cellular pathways safeguarding proteome function and balance are termed the “proteostasis network.” Martin aims to elucidate how the proteostasis network dynamically adapts to the needs of the cell and how it is challenged and rewired in diseases, especially cancer and neurodegenerative diseases. Identification of proteostasis factors that control formation, spread, and clearance of protein aggregates associated with neurodegenerative diseases will shed light on the disease mechanisms and reveal potential therapeutic targets.
Martin has received several highly prestigious awards, including the NIH Director’s New Innovator Award (2015), the Paul G. Allen Family Foundation’s Allen Distinguished Investigator Award (2015), and the NIH Pathway to Independence Award (2014). The Kampmann lab is affiliated with the Innovative Genomics Initiative and the Paul F. Glenn Center for Aging Research at UC Berkeley and UCSF.
CloseScientific Founder
Prashant Mali PhD
Scientific Founder and Advisor
View BioPrashant Mali PhD
Prashant is an Associate Professor in the Department of Bioengineering at the University of California San Diego. His research is in the fields of synthetic biology and regenerative medicine, with a long-term focus on developing tools for enabling gene and cell based human therapeutics. In this regard, he has helped pioneer the development of CRISPR-Cas9, a powerful genome editing tool derived from microbial systems, with wide applications in both basic biology and human therapeutics. More recently, he is focused on the development of RNA and protein targeting tools derived from endogenous human systems.
Prashant received his Bachelor’s and Master’s degrees in Electrical Engineering from the Indian Institute of Technology Bombay, a doctorate in Biomedical Engineering at the Johns Hopkins University, and a postdoctoral fellowship in the Department of Genetics at the Harvard Medical School. He has received multiple awards including the Siebel Scholar Award, the Burroughs Wellcome Career Award, the March of Dimes Basil O’Conner Scholar Award, the Kimmel Scholar Award, Kavli Frontiers of Science Fellow, and the Young Alumnus Achiever Award from the Indian Institute of Technology Bombay.
CloseScientific Founder
Hu Li PhD
Scientific Founder and Advisor
View BioHu Li PhD
Hu is an Associate Professor at the Mayo Clinic. His group is focused on systems pharmacology and individualized systems medicine. Li’s team is active in developing novel network tools and harnessing machine learning methods to study context-dependent activities of regulatory networks at genome-wide scale. The major theme in the research team is to develop novel computational methods that can detect meaningful biological information embedded in the sea of Big Data and uncover novel regulatory mechanisms that explain the properties of biological phenotypes to benefit individualized disease diagnosis, drug discovery, and precision medicine. The developed computational platforms can greatly illuminate the understanding of disease mechanisms underlying drugs’ modes of action, addressing key challenges in Big Data-oriented biomedical complex systems and will ultimately lead to precision medicine for each patient suffering from a devastating disease.
Hu completed his post-doctoral fellowship in systems biology at the Wyss Institute at Harvard Medical School and received his Ph.D. in computational biology and bioinformatics from the National University of Singapore.CloseClose